Increased prevalence of aminoglycoside resistance in clinical isolates of Escherichia coli and Klebsiella spp. in Norway is associated with the acquisition of AAC(3)-II and AAC(6')-Ib.
In this study, we show that the increasing prevalence of aminoglycoside resistance observed in Norway among clinical Escherichia coli and Klebsiella spp. isolates is mainly due to the presence of the aminoglycoside-modifying enzymes AAC(3)-II and AAC(6')-Ib. A frequent co-association of aminoglycoside resistance with Cefotaximase-München group 1 extended-spectrum β-lactamases was also observed.
Reference Centre for Detection of Antimicrobial Resistance, Department of Microbiology and Infection Control, University Hospital of North Norway, Tromsø, Norway.
Bjørg C
BC
Haldorsen
Reference Centre for Detection of Antimicrobial Resistance, Department of Microbiology and Infection Control, University Hospital of North Norway, Tromsø, Norway; Research Group for Host-Microbe Interactions, Department of Medical Biology, Faculty of Health Sciences, University of Tromsø, Tromsø, Norway.
Gunnar Skov
GS
Simonsen
Reference Centre for Detection of Antimicrobial Resistance, Department of Microbiology and Infection Control, University Hospital of North Norway, Tromsø, Norway; Research Group for Host-Microbe Interactions, Department of Medical Biology, Faculty of Health Sciences, University of Tromsø, Tromsø, Norway.
Arnfinn
A
Sundsfjord
Reference Centre for Detection of Antimicrobial Resistance, Department of Microbiology and Infection Control, University Hospital of North Norway, Tromsø, Norway. Electronic address: orjan.samuelsen@unn.no.
Orjan
O
Samuelsen
D000123:Acetyltransferases / Q000235:genetics*; D000617:Aminoglycosides / Q000494:pharmacology*; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D024881:Drug Resistance, Bacterial; D004926:Escherichia coli / Q000187:drug effects* / Q000201:enzymology / Q000235:genetics / Q000302:isolation & purification; D004927:Escherichia coli Infections / Q000453:epidemiology* / Q000382:microbiology; D006801:Humans; D007709:Klebsiella / Q000187:drug effects* / Q000201:enzymology / Q000235:genetics / Q000302:isolation & purification; D007710:Klebsiella Infections / Q000453:epidemiology* / Q000382:microbiology; D009664:Norway / Q000453:epidemiology; D015995:Prevalence
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D000123:Acetyltransferases; C019681:aminoglycoside acetyltransferase
AAC(3)-II; AAC(6′)-Ib; CTX-M; ESBL; RmtB